Welcome to our dedicated page for Clorox Co Del SEC filings (Ticker: CLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Clorox Company (NYSE: CLX) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its operations as a consumer products manufacturer in the polish and other sanitation good manufacturing industry. This SEC filings page aggregates those disclosures and pairs them with AI-powered summaries to help readers interpret the information more efficiently.
Key filings for CLX include annual reports on Form 10-K, which typically describe the company’s business segments—Health and Wellness, Household, Lifestyle and International—along with risk factors, discussion of strategy and detailed financial statements. Quarterly reports on Form 10-Q update investors on interim performance, including segment results, margin drivers, cash flow and the impact of initiatives such as the U.S. enterprise resource planning (ERP) transition and portfolio changes like the divestiture of the Better Health Vitamins, Minerals and Supplements business.
Clorox also uses current reports on Form 8-K to disclose material events. Recent 8-K filings have covered quarterly and annual financial results, supplemental financial information, and matters submitted to a shareholder vote at the annual meeting, including director elections, advisory votes on executive compensation and ratification of the independent registered public accounting firm. Other 8-Ks may address leadership changes or other significant corporate developments.
The company’s proxy statement on Form DEF 14A provides additional detail on governance, board composition, executive compensation, strategic priorities such as the IGNITE strategy and oversight of areas like risk management and sustainability. For those interested in ownership and compensation, this document is a primary source.
On this page, filings are updated as they are released to EDGAR. AI-generated highlights and plain-language explanations help clarify complex topics such as non-GAAP measures (for example, organic sales growth, adjusted EBIT and adjusted EPS), the effects of the ERP transition on reported results, and the rationale behind portfolio actions. Users can also review any available insider-related disclosures, such as Form 4 filings, to see reported transactions by directors and officers.
Whether you are analyzing Clorox’s segment performance, reviewing governance practices, or tracking shareholder votes and executive compensation, this filings hub offers structured access to the company’s regulatory record with tools designed to make lengthy documents more approachable.
Clorox Co (CLX) EVP and CFO Luc Bellet reported a routine tax-related share disposition. On vesting of restricted stock, the company withheld 244 shares of common stock at $103.63 per share to cover tax obligations, rather than selling shares in the open market.
After this withholding, Bellet directly holds 20,638 shares of Clorox common stock. Footnotes also note that this total includes 18 shares acquired through a dividend reinvestment feature under the company’s Stock Incentive Plan.
Clorox director Christopher J. Williams reported routine compensation-related awards of Deferred Stock Units. He acquired 265.3672 units on March 31, 2026 and 212.6390 units on February 13, 2026, with each unit representing one share of Clorox common stock.
Some units were acquired through dividend reinvestment under the Independent Directors' Deferred Compensation Plan and some in lieu of quarterly director fees. These Deferred Stock Units will be settled entirely in Clorox stock when Williams retires or otherwise leaves the board, bringing his reported Deferred Stock Unit balance to 22,074.5818 units held directly.
Clorox (CLX) director Russell J. Weiner reported routine compensation-related acquisitions of Deferred Stock Units. On February 13, 2026, he received 172.3630 Deferred Stock Units, and on March 31, 2026, he received 325.6779 Deferred Stock Units, each on a 1-for-1 basis linked to Clorox common stock.
According to the footnotes, some units were acquired through dividend reinvestment under the Independent Directors' Deferred Compensation Plan and others in lieu of quarterly director fees. The units will be settled entirely in Clorox stock upon his retirement or other termination of service as a director. Following these awards, his reported balance is 18,004.0034 Deferred Stock Units held directly.
Clorox director Matthew J. Shattock reported routine equity-based compensation in the form of deferred stock units. He acquired 506.6101 deferred stock units on March 31, 2026 and 191.2909 units on February 13, 2026, each on a 1-for-1 basis with Clorox common stock.
The units were received through dividend reinvestment and in lieu of quarterly director fees under the Independent Directors' Deferred Compensation Plan and will be settled in Clorox stock after his retirement or other termination of board service. Following these awards, he directly holds 20,126.2673 deferred stock units.
Clorox director Pierre R. Breber reported routine compensation-related awards of Deferred Stock Units tied 1-for-1 to Clorox common stock. On March 31, 2026, he acquired 325.6779 Deferred Stock Units, bringing his holdings to 3100.0674 units. On February 13, 2026, he had received an additional 27.0502 units.
According to the disclosures, some Deferred Stock Units were acquired through dividend reinvestment during the fiscal year under the Independent Directors' Deferred Compensation Plan and some were received in lieu of quarterly director fees. These units will be settled entirely in Clorox stock when Breber retires or otherwise leaves the board, and do not reflect open-market buying or selling.
Clorox director Stephanie Plaines reported awards of deferred stock units that increase her equity-based compensation stake. She acquired 265.3672 deferred stock units on March 31, 2026 and 72.7316 units on February 13, 2026, both at a stated price of $0.00 per unit as non-cash awards.
The units are credited 1-for-1 in relation to Clorox common stock and arise from dividend reinvestment during the fiscal year and receipt of deferred units instead of quarterly director fees under the Independent Directors' Deferred Compensation Plan. Following the latest award, she holds a total of 7,725.0486 deferred stock units, which will be settled entirely in Clorox stock upon her retirement or other termination of board service.
The Clorox Company completed its acquisition of GOJO Industries, makers of Purell, on April 1, 2026. Clorox purchased all issued and outstanding membership interests of GOJO under a membership interest purchase agreement with GOJO Industries Holdings and its shareholders. The acquired business will operate as Clorox Purell, led by President Carey Jaros, based in Akron, Ohio, with existing facilities remaining in Ashland, Cuyahoga Falls and Wooster, Ohio. Clorox describes the combination as expanding its health and hygiene portfolio and reinforcing its strategy to deliver comprehensive solutions for both consumers and institutional customers.
The Vanguard Group filed an Amendment No. 13 to a Schedule 13G/A reporting that it beneficially owns 0 shares of Clorox Co. Common Stock and holds 0% of the class. The filing explains an internal realignment effective January 12, 2026, with certain subsidiaries reporting ownership separately in reliance on SEC Release No. 34-39538.
Clorox executive Chris T. Hyder reported a small tax-related share disposition. On the vesting of restricted stock, 41 shares of Clorox common stock were withheld by the company at $108.73 per share to satisfy tax obligations, a routine non-market transaction.
After this withholding, Hyder directly holds 34,969 shares of Clorox common stock, which the disclosure notes includes 10 shares acquired through a dividend reinvestment feature of the company’s stock incentive plan.
Clorox executive Stacey Grier reported a small, routine share disposition tied to taxes rather than a market trade. On vesting of restricted stock, the company withheld 32 shares of common stock at a value of $108.73 per share to cover tax obligations.
After this tax-withholding disposition, Grier directly holds 32,116 Clorox shares. This total includes 10 shares acquired through a dividend reinvestment feature of the company’s stock incentive plan, indicating the filing reflects compensation and administrative activity rather than an open-market sale.